Adagene Past Earnings Performance

Past criteria checks 0/6

Adagene's earnings have been declining at an average annual rate of -2.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 17.9% per year.

Key information

-2.1%

Earnings growth rate

25.0%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate17.9%
Return on equity-56.3%
Net Margin-3,904.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Adagene makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:978 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241-32830
31 Mar 249-25833
31 Dec 2318-19937
30 Sep 2320-28947
30 Jun 2323-361057
31 Mar 2316-581169
31 Dec 229-801281
30 Sep 2211-821382
30 Jun 2213-841481
31 Mar 2211-781475
31 Dec 2110-731468
30 Sep 216-681460
30 Jun 212-621350
31 Mar 211-521242
31 Dec 201-431034
30 Sep 201-34928
30 Jun 201-28724
31 Mar 201-22520
31 Dec 190-17416
31 Dec 182-14316

Quality Earnings: 978 is currently unprofitable.

Growing Profit Margin: 978 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 978 is unprofitable, and losses have increased over the past 5 years at a rate of 2.1% per year.

Accelerating Growth: Unable to compare 978's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 978 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 978 has a negative Return on Equity (-56.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:55
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adagene Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Claire WangChina Renaissance Securities
Bing ZhaoChina Renaissance Securities
Ziyi ChenGoldman Sachs